HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report
Lung Cancer: Targets and Therapy · 2026-05 · Volume 17 · 1-4
DOI: 10.2147/lctt.s600499 ↗Kurz gefasst
Fallbericht in der Zeitschrift Lung Cancer: Targets and Therapy, 2026-05. Verfasst von Misako Nagasaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
- Department of Medicine, St Marianna University School of Medicine, Kawasaki, Japan.
ORCID-Profile: Misako Nagasaka, Zhaohui L Arter, Cathleen J Park
Zitieren
APA
Nagasaka, M., Arter, Z. L., Park, C. J., Sarkari, A., & Ou, S. I. (2026). HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report. Lung Cancer: Targets and Therapy, Volume 17, 1-4. https://doi.org/10.2147/lctt.s600499
Vancouver
Nagasaka M, Arter ZL, Park CJ, Sarkari A, Ou SI. HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report. Lung Cancer: Targets and Therapy. 2026;Volume 17:1-4. doi:10.2147/lctt.s600499
BibTeX
@article{Nagasaka2026,
author = {Nagasaka, Misako and Arter, Zhaohui L and Park, Cathleen J and Sarkari, Akshat and Ou, Sai-Hong Ignatius},
title = {HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report},
journal = {Lung Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 17},
pages = {1--4},
doi = {10.2147/lctt.s600499}
}
EUVIMED